PHARMACEUTICAL PREPARATIONS
First Tracks Biotherapeutics, Inc. Ordinary Shares
TRAX
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
Open XNAS
Fundamentals
Key company ratios and reported financial statements.
Key ratios
Valuation
- Market capitalization
- $1.96B
- Price / earnings
- —
- Price / book
- 12.96×
- Price / sales
- —
- EV / sales
- —
- EV / EBITDA
- -10.9×
Profitability
- Earnings per share
- -$3.74
- Return on assets
- -92.15%
- Return on equity
- -104.01%
- Dividend yield
- 0%
Liquidity and leverage
- Debt / equity
- 0×
- Current ratio
- 9.16×
- Quick ratio
- 9.16×
- Cash ratio
- 8.6×
Cash flow
- Price / cash flow
- —
- Price / free cash flow
- —
- Free cash flow
- -$112.28M
Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.
| Line item | Q3 FY2026 Sep 30, 2026 | Q2 FY2026 Jun 30, 2026 |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of revenue | $0 | $0 |
| Gross profit | $0 | $0 |
| Selling, general and administrative | $9M | $9.29M |
| Research and development | $23.85M | $25.64M |
| Total operating expenses | $32.84M | $34.94M |
| Operating income | -$32.84M | -$34.94M |
| Interest expense | $0 | $0 |
| Income before taxes | -$31.36M | -$33.37M |
| Income taxes | $0 | $0 |
| Net income | -$31.36M | -$33.37M |
| Net income attributable to common shareholders | -$31.36M | -$33.37M |
| EBITDA | -$32.75M | -$34.83M |
| Basic earnings per share | -$0.88 | -$0.95 |
| Diluted earnings per share | -$0.88 | -$0.95 |
Recent news
Company coverage with links to the original publishers.
No recent company news found.
Dividends
Declared distributions and recorded event dates. Forecasts are not shown.
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.
No stock split records found.